In respect to thrombotic and major bleeding outcomes, no significant difference in the composite net clinical benefit outcome or any of the individual component outcomes was observed when comparing rivaroxaban and VKA in agreement with the ROCKET–AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) randomized controlled trial.28 Here, F10 is linked to atrial fibrillation.